Zepbound
PERSON · 20 article mentions
Recent mentions
- Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why
- Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
- What do you mean my new smart scale is ‘built for GLP-1 users’?
- Here are JPMorgan's favorite stocks heading into June
- Serena Williams, 44, to return to tennis in Queen's doubles
- CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
- Jim Cramer says this data center stock could soar if more analysts cover it
- Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
- New weight-loss shot appears to outperform other obesity drugs on market
- Eli Lilly says next-generation weight loss drug clears crucial obesity trial